• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600829.SS
Share

HPGC Renmintongtai Pharmaceutical Corporation Stocks

CN¥ 8.23Last Updated 10.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 718.53M

CN¥ 8.23
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Low dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HPGC Renmintongtai Pharmaceutical Corporation is a pharmaceutical enterprise actively involved in the wholesale and retail distribution of diverse medicinal products across China and internationally. Its extensive product portfolio encompasses traditional Chinese medicines, herbal remedies, chemical preparations, antibiotics, biologics, biochemical drugs, medical equipment, and health-related items. The company also extends its operations to include logistics services, specifically warehousing and distribution. Additionally, it offers comprehensive hospital services covering medical treatment, scientific research, disease prevention, health promotion, rehabilitation, blood purification, and renal disease management. Through its e-commerce platform, HPGC Renmintongtai markets a broad selection of items, including Chinese and Western pharmaceuticals, traditional Chinese herbs, nutritional supplements, medical devices, cosmetics, and everyday necessities. The company maintains a significant retail presence with 319 chain stores located throughout Heilongjiang Province. Established in 1950 and headquartered in Harbin, China, HPGC Renmintongtai Pharmaceutical Corporation operates as a subsidiary of Harbin Pharmaceutical Group Co., Ltd.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair val

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.07.2026 18:01

"Buffett in a Skirt": How Hetty Green Built an Empire on Crises and Saved Wall Street

12.07.2026 15:01

"The 30-Second Rule": How Investors Can Learn to Think Things Through Before Making Trades

12.07.2026 05:26

The U.S. announced a third wave of strikes against Iran following the closure of the Strait of Hormuz

11.07.2026 19:01

A Triumph for City Governments? How China’s Scaling Model Will Change the Global AI Market

11.07.2026 16:01

Highlights from Small-Caps: Royce Fund Forecast, Trump's Sons' Investments, the Chewy Case Study

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026